Latest / tv.qiagenbioinformatics.com
Oncology: De-risking target evaluation and indication expansion with curated...
The early stages of drug development are inherently high-risk; molecule screening, target evaluation and lead refinement can take years and cost millions of dollars – often have little to show for the effort. Indication expansion and drug repurposing can open new avenues of possibility, after careful evaluation of the relationships between the drug, its targets and the new disease context. These connections can be uncovered by mining curated, causal knowledge graphs, which inform smarter target identification.
Learn how to evaluate targets and drugs in this oncology-focused webinar, which…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.